What You Should Know:
– Ultromics, a pioneer in AI-driven cardiology solutions secures $55M in Series C financing co-led by L&G, Allegis Capital, and Lightrock, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. Major U.S. health systems, including University of Chicago Medicine and UCM Ventures, also participated in the round.
– Built on years of clinical study and hundreds of thousands of echo scans, Ultromics offers the first FDA-cleared, Medicare-reimbursed AI technology to help clinicians detect HFpEF (Heart Failure with preserved Ejection Fraction) and cardiac amyloidosis, two of the most elusive forms of heart failure.
Addressing the Mounting Heart Failure Crisis
Heart failure is on the rise, costs are mounting, and millions of patients are still going undiagnosed, especially those with harder-to-detect forms like HFpEF and cardiac amyloidosis. In the U.S. alone, heart failure accounts for over $30 billion in annual healthcare costs, a number projected to exceed $70 billion by 2030. Clinicians often rely on subjective interpretation of echocardiograms, leading to missed or delayed diagnoses even when patients are actively seeking care. Up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is frequently mistaken for more common forms of heart disease, leaving patients untreated until symptoms worsen or irreversible damage occurs.
Ultromics addresses this diagnostic blind spot by using AI to extract hidden disease signals from standard echocardiograms, enabling earlier, more accurate detection of complex heart conditions—without requiring new hardware or disrupting clinical workflows. Its FDA-cleared EchoGo® platform supports diagnosis of HFpEF and cardiac amyloidosis. Trained and validated on one of the largest real-world echo datasets globally, EchoGo® generates real-time probability scores to help cardiologists identify high-risk patients earlier than traditional methods. EchoGo® is fully reimbursed under Medicare, making it scalable across hospitals, clinics, and health systems nationwide.
Clinical Performance and Strategic Expansion
Ultromics has analyzed over 430,000 echocardiograms to date. In clinical studies, EchoGo® improved the detection of HFpEF by 73.6% compared with standard clinical risk scores. The company’s latest diagnostic model for cardiac amyloidosis, validated in a global study of 18 institutions and published in the European Heart Journal, outperformed current clinical risk scores while distinguishing the disease from similar conditions. These findings reinforce the urgency and impact of deploying FDA-cleared, AI-powered detection tools like Ultromics in everyday practice.
The company is now expanding across the U.S. to bring this capability to hospitals and echo labs with high volumes of at-risk patients, aiming to make AI-enhanced diagnostics a default step in the cardiac workup. Ultromics is also expanding its pipeline to include additional cardiac conditions, new distribution channels, and deeper partnerships with health systems and clinical leaders.
“The reality is, hospitals already have the data, they just haven’t had the tools to extract the more subtle diagnostic signals from it. By analyzing routine echocardiograms with AI, we’re helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses,” said Ross Upton, PhD, CEO and Founder, Ultromics. “We’ve spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis.”
